We report the first exocyclically metallated tetrapyridinoporphyrazine, [tetrakis-(trans-Pt(NH₃)₂Cl)-tetra(3,4-pyrido)porphyrazine-zinc(II)](NO₃)₄ (4), synthesized in a multistep synthesis starting from 3,4-pyridinedicarbonitrile (1). The synthetic procedure involved a platination reaction of the intermediate tetra(3,4-pyrido)porphyrazine-zinc(II) (2), whereby the zinc(II) enhanced the solubility of the intermediate enabling the platination reaction. A similar approach to synthesize [tetrakis-(trans-Pt(NH₃)₂Cl)-tetra(3,4-pyrido)porphyrazine](NO₃)₄ (5) failed due to the unsuitable solubility properties of the intermediate tetra(3,4-pyrido)porphyrazine (3). The final product 4 and the intermediates were characterized, the photochemical and photophysical properties were determined and the photocytotoxicities were investigated. We demonstrate that the platinated tetra-pyridinoporphyrazine 4 is a potential photosensitizer for photodynamic therapy (PDT).

中文翻译：

---

环外金属化四吡啶并卟啉为光动力疗法的潜在光敏剂†

我们报告第一外环金属化四吡啶并卟啉，[四-（反式-Pt（NH ₃）₂ Cl）-四（3,4-吡啶基）卟啉-锌（II）]（NO ₃）₄（4）从3，4-吡啶二甲腈（1）开始的多步合成。合成步骤涉及中间体四（3,4-吡啶基）卟啉-锌（II）（2）的电镀反应，其中锌（II）增强了中间体的溶解度，从而可以进行电镀反应。合成[tetrakis-（反-Pt（NH ₃）₂ Cl）的-四（3,4-吡啶并）四氮杂卟啉]（NO ₃）₄（5）由于没有中间四（3,4-吡啶并）四氮杂卟啉（的不合适的溶解度性质3）。表征最终产物4和中间体，确定其光化学和光物理性质，并研究光细胞毒性。我们证明，铂化的四吡啶并卟啉4是一种潜在的光敏剂，用于光动力疗法（PDT）。